Skip to main content
. 2020 Jun;32(3):370–382. doi: 10.21147/j.issn.1000-9604.2020.03.08

2. Efficacy-evaluable patients with OC treated with fluzoparib ≥120 mg/d. OC, ovarian cancer; PR, partial response; PFI, progression-free interval; #, progression-free survival censor (stop treatment without progression or death); +, breast cancer susceptibility genes (BRCA) mutation.

2